Overview
ZURA market data
Price History
ZURA price chart · 1M
- O
- 6.00
- H
- 6.01
- L
- 5.84
- C
- 5.85
- Vol
- 40,752.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $6.00
- Previous Close
- $6.00
- Day High
- $6.01
- Day Low
- $5.84
- 52 Week High
- $7.02
- 52 Week Low
- $3.29
- 7 Day Return
- +1.83%
- 30 Day Return
- +5.79%
- 90 Day Return
- +36.05%
- 1 Year Return
- +16.65%
- Daily Notional Volume
- $238.4K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.72 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.05 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.88 – $7.44 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $566.8M · P/B 1.11.
Company News
8-K filing — Zura Bio Ltd (ZURA)SEC EDGAR · Aug 17, 2026, 11:00 AM
Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22Benzinga · Aug 12, 2026, 4:00 PM
Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20Benzinga · Aug 12, 2026, 12:28 PM
Zura Bio Q2 EPS $(0.21) Misses $(0.20) EstimateBenzinga · Aug 11, 2026, 11:43 AM
William Blair Initiates Coverage On Zura Bio with Outperform RatingBenzinga · Jul 8, 2026, 7:00 PM
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead TherapyBenzinga · Jul 8, 2026, 5:30 PM
Wedbush Reiterates Outperform on Zura Bio, Maintains $15 Price TargetBenzinga · Jul 1, 2026, 2:05 PM
Zura Bio Completes Enrollment In Phase 2 TibuSHIELD Trial of Tibulizumab in Adults With HSBenzinga · Jun 29, 2026, 11:35 AM